Literature DB >> 34015936

Long Noncoding RNA Cardiac Physiological Hypertrophy-Associated Regulator Induces Cardiac Physiological Hypertrophy and Promotes Functional Recovery After Myocardial Ischemia-Reperfusion Injury.

Rongrong Gao1, Lijun Wang2,3, Yihua Bei2,3, Xiaodong Wu1, Jiaqi Wang2,3, Qiulian Zhou2,3, Lichan Tao4, Saumya Das5, Xinli Li1, Junjie Xiao2,3.   

Abstract

BACKGROUND: The benefits of exercise training in the cardiovascular system have been well accepted; however, the underlying mechanism remains to be explored. Here, we report the initial functional characterization of an exercise-induced cardiac physiological hypertrophy-associated novel long noncoding RNA (lncRNA).
METHODS: Using lncRNA microarray profiling, we identified lncRNAs in contributing the modulation of exercise-induced cardiac growth that we termed cardiac physiological hypertrophy-associated regulator (CPhar). Mice with adeno-associated virus serotype 9 driving CPhar overexpression and knockdown were used in in vivo experiments. Swim training was used to induce physiological cardiac hypertrophy in mice, and ischemia reperfusion injury surgery was conducted to investigate the protective effects of CPhar in mice. To investigate the mechanisms of CPhar's function, we performed various analyses including quantitative reverse transcription polymerase chain reaction, Western blot, histology, cardiac function (by echocardiography), functional rescue experiments, mass spectrometry, in vitro RNA transcription, RNA pulldown, RNA immunoprecipitation, chromatin immunoprecipitation assay, luciferase reporter assay, and coimmunoprecipitation assays.
RESULTS: We screened the lncRNAs in contributing the modulation of exercise-induced cardiac growth through lncRNA microarray profiling and found that CPhar was increased with exercise and was necessary for exercise-induced physiological cardiac growth. The gain and loss of function of CPhar regulated the expression of proliferation markers, hypertrophy, and apoptosis in cultured neonatal mouse cardiomyocytes. Overexpression of CPhar prevented myocardial ischemia reperfusion injury and cardiac dysfunction in vivo. We identified DDX17 (DEAD-Box Helicase 17) as a binding partner of CPhar in regulating CPhar downstream factor ATF7 (activating transcription factor 7) by sequestering C/EBPβ (CCAAT/enhancer binding protein beta).
CONCLUSIONS: Our study of this lncRNA CPhar provides new insights into the regulation of exercise-induced cardiac physiological growth, demonstrating the cardioprotective role of CPhar in the heart, and expanding our mechanistic understanding of lncRNA function, as well.

Entities:  

Keywords:  RNA, long noncoding; exercise; heart failure; reperfusion injury

Mesh:

Substances:

Year:  2021        PMID: 34015936     DOI: 10.1161/CIRCULATIONAHA.120.050446

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  18 in total

1.  Fasudil Ameliorates Osteoporosis Following Myocardial Infarction by Regulating Cardiac Calcitonin Secretion.

Authors:  Chengyu Xiang; Yeqian Zhu; Maohua Xu; Dingguo Zhang
Journal:  J Cardiovasc Transl Res       Date:  2022-05-12       Impact factor: 4.132

Review 2.  Animal Models of Exercise From Rodents to Pythons.

Authors:  Margaret H Hastings; Jonathan J Herrera; J Sawalla Guseh; Bjarni Atlason; Nicholas E Houstis; Azrul Abdul Kadir; Haobo Li; Cedric Sheffield; Anand P Singh; Jason D Roh; Sharlene M Day; Anthony Rosenzweig
Journal:  Circ Res       Date:  2022-06-09       Impact factor: 23.213

3.  miR-486 attenuates cardiac ischemia/reperfusion injury and mediates the beneficial effect of exercise for myocardial protection.

Authors:  Yihua Bei; Dongchao Lu; Christian Bär; Shambhabi Chatterjee; Alessia Costa; Isabelle Riedel; Frank C Mooren; Yujiao Zhu; Zhenzhen Huang; Meng Wei; Meiyu Hu; Sunyi Liu; Pujiao Yu; Kun Wang; Thomas Thum; Junjie Xiao
Journal:  Mol Ther       Date:  2022-01-22       Impact factor: 12.910

4.  Exercise-Induced Long Noncoding RNAs As New Players in Cardiac Hypertrophy.

Authors:  Catherine A Makarewich; Thomas Thum
Journal:  Circulation       Date:  2022-04-18       Impact factor: 39.918

Review 5.  Signaling cascades in the failing heart and emerging therapeutic strategies.

Authors:  Xin He; Tailai Du; Tianxin Long; Xinxue Liao; Yugang Dong; Zhan-Peng Huang
Journal:  Signal Transduct Target Ther       Date:  2022-04-23

6.  Long chain noncoding RNA-ROR promotes hypoxic injury of cardiomyocytes by targeting the miR-145/HAX-1 axis.

Authors:  Ya Yang; Qianmei Tang; Yu Li; Lianjing Dai; Minfeng Li; Yongxin Fu
Journal:  J Thorac Dis       Date:  2022-05       Impact factor: 3.005

7.  lncExACT1 and DCHS2 Regulate Physiological and Pathological Cardiac Growth.

Authors:  Haobo Li; Lena E Trager; Xiaojun Liu; Margaret H Hastings; Chunyang Xiao; Justin Guerra; Samantha To; Guoping Li; Ashish Yeri; Rodosthenis Rodosthenous; Michael G Silverman; Saumya Das; Amrut V Ambardekar; Michael R Bristow; Juan Manuel González-Rosa; Anthony Rosenzweig
Journal:  Circulation       Date:  2022-02-04       Impact factor: 39.918

8.  Animal exercise studies in cardiovascular research: Current knowledge and optimal design-A position paper of the Committee on Cardiac Rehabilitation, Chinese Medical Doctors' Association.

Authors:  Yihua Bei; Lei Wang; Rongjing Ding; Lin Che; Zhiqing Fan; Wei Gao; Qi Liang; Shenghui Lin; Suixin Liu; Xiao Lu; Yuqin Shen; Guifu Wu; Jian Yang; Guolin Zhang; Wei Zhao; Lan Guo; Junjie Xiao
Journal:  J Sport Health Sci       Date:  2021-08-25       Impact factor: 7.179

9.  PPARγ Mediates the Cardioprotective Roles of Danlou Tablet After Acute Myocardial Ischemia-Reperfusion Injury.

Authors:  Meng Wei; Mengying Guo; Xinxiu Meng; Lin Li; Hongyun Wang; Mingxue Zhang; Yihua Bei
Journal:  Front Cardiovasc Med       Date:  2022-03-25

10.  Comprehensive Analysis of Key m6A Modification Related Genes and Immune Infiltrates in Human Aortic Dissection.

Authors:  Fanxing Yin; Hao Zhang; Panpan Guo; Yihao Wu; Xinya Zhao; Fangjun Li; Ce Bian; Chen Chen; Yanshuo Han; Kun Liu
Journal:  Front Cardiovasc Med       Date:  2022-03-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.